Ultresa Approval History
- FDA approved: Yes (First approved March 1st, 2012)
- Brand name: Ultresa
- Generic name: pancrelipase
- Dosage form: Delayed Release Capsules
- Company: Allergan plc
- Treatment for: Pancreatic Exocrine Dysfunction
Ultresa (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Development History and FDA Approval Process for Ultresa
|Mar 1, 2012||Aptalis Pharma Announces FDA Approval of Ultresa (Pancrelipase) Delayed Release Capsules|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.